Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Intercellular connection" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Direct contact and connection of a cell with a neighboring cell.
Compositions and methods for treating cystic fibrosis
InactiveUS20100303917A1Increased mucus secretionReduce airflowBiocidePowder deliveryTobramycinCell membrane
Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
Owner:REVALESIO CORP
Compositions and methods for treating asthma and other lung disorders
InactiveUS20100008997A1Powder deliveryOrganic active ingredientsObstructive Pulmonary DiseasesOxygen
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.
Owner:REVALESIO CORP
Compositions and methods for treating digestive disorders
Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treating cystic fibrosis
Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with tobramycin (including TOBI) for use against bacterial infection, and synergy with a bronchiodilator. In particular embodiments, the electrokinetically-generated fluids or therapeutic compositions and methods comprise combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). In certain aspects, the methods comprise regulating or modulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
Owner:REVALESIO CORP
Compositions and methods for treating cystic fibrosis
InactiveUS20100004189A1Increased mucus secretionReduce airflowBiocideCarbohydrate active ingredientsTobramycinCell membrane
Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
Owner:REVALESIO CORP
Compositions and methods for treating asthma and other lung disorders
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent.
Owner:REVALESIO CORP
Compositions and methods for treating multiple sclerosis
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treatment of neurodegenerative diseases
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD)) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential and / or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treating multiple sclerosis
InactiveUS20100015235A1Sufficient amountPowder deliveryOrganic active ingredientsDiseaseCell membrane
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treatment of taupathy
Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and / or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
Owner:REVALESIO CORP
Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized gas-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized, at least in part, with molecular gas (e.g., oxygen).
Owner:REVALESIO CORP
Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized gas-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized, at least in part, with molecular gas (e.g., oxygen).
Owner:REVALESIO CORP
Compositions and methods for treating asthma and other lung disorders
InactiveUS20120114702A1Sufficient amountAntibacterial agentsPowder deliveryObstructive Pulmonary DiseasesOxygen
Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) comprising administering a therapeutic composition comprising at least one electrokinetically altered fluid comprising an ionic aqueous solution of charge-stabilized oxygen containing nanostructures as disclosed herein, or comprising administering a nonelectrokinetic superoxygenated aqueous solution The methods preferably comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e g, membrane receptors, (e g, G protein-coupled receptors, and intercellular junctions)) Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent (e g, albuterol, etc).
Owner:REVALESIO CORP
Cell sheet engineering and preparation method thereof
InactiveCN101629162AGet the effect of graftingNo deformation damageTissue cultureProsthesisPoly(N-isopropylacrylamide)Cell sheet
The invention belongs to the field of tissue engineering, in particular to a cell sheet engineering and a preparation method thereof. The cell sheet is prepared with the following methods: firstly, an electron accelerator is used for radiating on the surface of the cell culture supporter for synthesizing poly-N-isopropylacrylamide; then, temperature is controlled to cause the poly-N-isopropylacrylamide to be hydrophobicity phase, and cells are cultured on the phase; temperature is changed to cause hydrogel to be hydrophilic phase; with the method that a polymeric membrane is used for adsorbing or a clamp is used for clamping to separate the cell sheet engineering. Obtained cell sheets are cultivated by multiple stratification, or protein adhering liquid is used for adhering to obtain multiple layers of cell sheets. The cell sheet obtained by the invention can keep desmosome structure between cells, ZO-1 tight connection structure and the connection structure between other cells, can keep basement membrane protein and a plurality of components thereof relative to adhesion, such as integrin and the like and has certain strength.
Owner:JINAN UNIVERSITY +1
Copolymerized nano composite hydrogel for intelligent separation of cell sheets as well as preparation method and application thereof
InactiveCN102516473AEasy to prepareReaction is easy to controlArtificial cell constructsVertebrate cellsCell-Extracellular MatrixDesorption
The invention discloses a copolymerized nano composite hydrogel for intelligent separation of cell sheets as well as a preparation method and application of the copolymerized nano composite hydrogel. The preparation method comprises the steps of: dispersing laponite in water, stirring to obtain homogenous and transparent dispersion, then sequentially adding polyethylene glycol macromonomer and N-isopropyl acrylamide monomer, uniformly stirring, removing oxygen, adding an initiator, transferring reaction liquid to a glass test tube and a reaction mold, sealing, and carrying out in-situ radicalpolymerization reaction at 15-25 DEG C to obtain a target product. The prepared copolymerized nano composite hydrogel has good mechanical performance and temperature sensitivity, and can be used for cell culture and rapid desorption of the cell sheets. The copolymerized nano composite hydrogel is suitable for cell growth, and can also realize rapid and automatic desorption of the cell sheets fromthe surface of the hydrogel by reducing the ambient temperature of the gel, thus tissue fibrosis and inflammation generation caused by use of biodegrable supports are avoided, and the damage to extracellular matrix and intercellular connection caused by use of trypsogen is avoided.
Owner:SOUTH CHINA UNIV OF TECH
Compositions and methods for treating insulin resistance and diabetes mellitus
Owner:REVALESIO CORP
Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
ActiveUS20160355559A1Easy to manageSenses disorderPeptide/protein ingredientsRetinal pigment epithelial cellFhit gene
A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.
Owner:RETINAL SOLUTIONS LLC
Tumour cell migration capability evaluation method and application
InactiveCN103184263ALow costSimple and fast operationMicrobiological testing/measurementTumor/cancer cellsCancer cellCulture cell
The invention provides a tumour cell migration capability evaluation method. The tumour cell migration capability evaluation method comprises the following steps of: collecting and culturing tumour cells, namely collecting tumour cells to be evaluated to obtain cell suspension, and culturing the cell suspension; and evaluating tumour cell migration capability, namely injecting a tumour cell anti-migration drug, and then detecting cell morphology, cell layer area, connecting strength between cells and a polyacrylamide culture substrate and connecting strength among cells as tumour cell migration capability evaluation criterions. The tumour cell migration capability evaluation method provided by the invention has the characteristics of low cost, easy operation, easily discriminated result and high speed and accuracy. By utilizing the tumour cell migration capability evaluation method, molecular biology and cell biology means are taken as basis, cancer cells with strong transitivity are screened, an in vitro cancer cell migration model is built, drugs with potential inhibiting effect on tumour cell migration can be effectively screened, a simple and practicable method is provided for high-throughput drug screening, and a development period of a new drug is shortened.
Owner:SHANDONG XINBO PHARMA R&D
Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells cells to norrin. Upon sufficient contact time, for norrin to selectively up- regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.
Owner:RETINAL SOLUTIONS LLC
Compositions and methods for treating insulin resistance and diabetes mellitus
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Application of keratinocyte growth factor-2 in preparation of medicines for preventing and curing lung injury
InactiveCN101822821AKeep the connection steadyPromote hyperplasiaPeptide/protein ingredientsRespiratory disorderFactor iiStress failure
The invention relates to an application of keratinocyte growth factor-2 in the preparation of medicines for preventing and curing lung injury. The invention has the advantages that single-medicine or medicine combination scheme is used to recombine human keratinocyte growth factor-2 (KGF-2) to cure and prevent lung injury / respiratory distress syndrome caused by any factor; and the lung injury / respiratory distress syndrome is in an important position of the special medicine such as the treatment of high altitude lung injury, the military medicine, the sports medicine and the treatment of lung injury / respiratory distress syndrome caused by other diseases. The above diseases can be subclinical, mild, moderate, severe or life-threatening lung injury. Researches show that KGF-2 can maintain the dynamic equilibrium of alveolar surfactants to promote hyperplasia, migrate cells and repair lung injury; and the KGF-2 plays an important role in protecting air-blood barrier to be intact, maintaining the cytoskeletal and intercellular splicing homeostasis, promoting the lung water to be removed and reducing or avoiding alveolus-capillary stress failure.
Owner:SHANGHAI XINSHENGYUAN BIOLOGICAL MEDICAL +1
Compositions and methods for treating inflammation
Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Methods of wound care and treatment
Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Preparation method of CIK in three-dimensional environment
InactiveCN105316290AHigh activityPromote growthBlood/immune system cellsCrystallographySpatial structure
The invention discloses a preparation method of CIK in three-dimensional environment. The preparation method includes following steps: taking aprotinin to dissolve fibrinogen to obtain a solution A; preparing a solution B containing thrombin; obtaining a mononuclear cell, and mixing the mononuclear cell with the solution A and the solution B to be solidified to obtain a pre-induction mixture; performing induced culture on the pre-induction mixture containing the mononuclear cell to obtain CIK. The preparation method has the advantages that the mononuclear cell is mixed with the solution A and the solution B to enable the mononuclear cell to be positioned in fibrin gel environment, and fibrin gel can simulate three-dimensional growing microenvironment of in-vivo cells, so that sufficient growing space and spatial structure supportive of intercellular connection are provided for the cells, number of amplification times of the cells is increased remarkably, and activity of the cells obtained is higher.
Owner:SHEN ZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD
Compositions and methods for treatment of taupathy
Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and / or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
Owner:REVALESIO CORP
Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
Owner:RETINAL SOLUTIONS LLC
Compositions and methods for treating cystic fibrosis
Owner:REVALESIO CORP
Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.
Owner:RETINAL SOLUTIONS LLC
Method for constructing genetic character chimeric multi-cellar structure
InactiveCN104212758ASimple methodSave operating timeVertebrate cellsArtificial cell constructsCulture fluidImmunofluorescence staining
The invention relates to the biotechnical field, and discloses a method for constructing a genetic character chimeric multi-cellar structure. The method comprises the following steps: carrying out immunofluorescence staining on cell communities with different genetic backgrounds and needing chimericity, and observing to determine whether the above cells have intercellular junctions or not; mixing the cells with the intercellular junctions, adding a culture solution, placing the obtained product in a low protein adsorption centrifuge tube, allowing the centrifuge tube to stand at room temperature for 10-20min in order to make the cells precipitate to the bottom of the centrifuge tube, taking out the cells and the culture solution, placing the obtained product in a container, and growing to form a three dimensional structure with functions; and respectively labeling the cells with different genetic backgrounds, having no intercellular junctions and needing junctions by complementary nucleic acid single strands connected with NHS, mixing the labeled cells, placing the obtained product in the container, and growing to form the three-dimensional structure with functions. The method has the advantages of operation time shortening, simplicity, efficiency improvement and good chimeric effect.
Owner:FUDAN UNIV
Compositions and methods for treating inflammation
Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com